ライフサイエンスコーパス: EUS

1 EUS and MRI detect pancreatic lesions better than CT.

2 EUS appears useful to stage objectively and evaluate the

3 EUS can also guide needle aspiration of these lesions to

4 EUS detected malignant mediastinal lymphadenopathy more

5 EUS facilitates endoscopic drainage of pancreatic fluid

6 EUS findings may have a significant impact on assessment

7 EUS FNA is more accurate for nodal staging and impacts o

8 EUS FNA resulting in a higher/worse stage than CT (41 pa

9 EUS FNA should be included in the preoperative staging a

10 EUS FNA was more sensitive (83% vs. 29%; P < 0.001) than

11 EUS had a sensitivity of 100% and specificity of 80% for

12 EUS has a central role in the initial anatomic staging o

13 EUS has an increasing role in treatment with fiducial pl

14 EUS has been invariably more accurate than computed tomo

15 EUS has evolved and is now dominated by the application

16 EUS is an accurate diagnostic tool for the detection of

17 EUS is an indispensable tool in making a preoperative di

18 EUS is inaccurate for staging after radiation and chemot

19 EUS is inaccurate for staging after radiation therapy an

20 EUS is limited for staging distant metastases (M), and t

21 EUS is superior to OGD for detecting GOV in children wit

22 EUS played a significant role in identifying patients wi

23 EUS plus EBUS also had higher sensitivity and higher neg

24 EUS precluded surgery in 9 patients (12%) and influenced

25 EUS reflex electromyographic activity (EMG), innervation

26 EUS regions were marked on the maps.

27 EUS results have shown accuracy in the range of 75% for

28 EUS showed prominent mucosa, but no significant findings

29 EUS T plus N and postsurgery T plus N correlation showed

30 EUS tumor stages were as follows: TO, n = 1; T1, n = 8;

31 EUS was able to detect small metastases (less than 1 cm)

32 EUS was defined as a threshold >10 mA.

33 EUS was identified in the infarct in all 14 patients (11

34 EUS was performed when feasible.

35 EUS, MRI, and EUA are accurate tests for determining fis

36 EUS-FNA accurately and safely evaluates solid peri-intes

37 EUS-FNA as a first test (after CT) has high diagnostic y

38 EUS-FNA established tissue diagnosis in 70% of cases.

39 EUS-FNA is able to detect occult metastasis to the CLNs

40 EUS-FNA sensitivity, specificity, and accuracy was 92%,

41 EUS-FNA was performed in 457 patients with 554 lesions.

42 EUS-FNA was significantly better than CT at detecting di

43 EUS-FNA with histology of the specimens is a sensitive a

44 EUS-FNA, CT, and positron emission tomography detected m

45 EUS-guided fine-needle aspiration was performed on sites

46 EUS-guided RTFNA is a safe and accurate method for perfo

47 EUS-RTFNA allows for local staging and tissue diagnosis

48 ave a more indolent clinical course; and (3) EUS-FNA may be useful for the diagnosis and management o

49 accuracy of all 3 modalities was > or =85%: EUS 29 of 32 (91%, confidence interval [CI] 75%-98%), MR

50 All gastric lymphomas had an abnormal EUS: eight with discrete tumor masses and eight with gas

51 f the pancreas to the digestive tract allows EUS to obtain detailed images of this organ.

52 association with H pylori on initial EGD and EUS biopsies.

53 ses had very low-amplitude electrograms, and EUS could not be identified from electrogram amplitude a

54 In summary, ERCP and EUS are important tools for the management of benign and

55 he literature over the last year in ERCP and EUS as they apply to specific pancreatic disorders.

56 performance characteristics of CT, EUS, and EUS FNA for preoperative nodal staging of esophageal car

57 , and tumor stage determined by CT, EUS, and EUS FNA were associated with treatment decisions (P < 0.

58 re prospectively evaluated with CT, EUS, and EUS FNA.

59 , but most of the emphasis is on EUS-FNA and EUS-guided interventions.

60 TBNA, EBUS-FNA, and EUS-FNA performed sequentially as a single combined proc

61 Enhanced staging with laparoscopy and EUS helped in proper selection of patients and better ch

62 CT, MRI, and EUS detected a pancreatic abnormality in 11%, 33.3%, and

63 In 9 of 16 patients the results of OGD and EUS were concordant, that is, both positive (2) or both

64 al transplant underwent simultaneous OGD and EUS.

65 Clinical response and EUS staging were correlated with surgical pathology.

66 on of submucosal tumors of the GI tract, and EUS criteria have been devised for the identification an

67 n pancreatic malignancy and ERCP, as well as EUS can identify and sample the solid and cystic lesions

68 e role of EUS-guided fine-needle aspiration (EUS FNA) in this setting is unclear.

69 y of EUS, EUS-guided fine needle aspiration (EUS-fine needle aspiration), emerging cytologic markers

70 , ultrasound-guided, fine-needle aspiration (EUS-FNA) biopsy and were resected.

71 ic ultrasound-guided fine-needle aspiration (EUS-FNA) for diagnosis of metastases to the pancreas.

72 opic ultrasound with fine needle aspiration (EUS-FNA) remain the preferred methods.

73 ic ultrasound-guided fine needle aspiration (EUS-FNA) was allowed as an alternative procedure.

74 ic ultrasound-guided fine needle aspiration (EUS-FNA) was evaluated as a single test for the diagnosi

75 ic ultrasound-guided fine-needle aspiration [EUS-FNA]) is capable of sampling lymph nodes for PCR ana

76 Pathologic staging can be achieved at EUS using fine-needle aspiration (FNA) to obtain cytolog

77 graphy-guided fine-needle aspiration biopsy (EUS-FNA) permits cytological confirmation of EUS finding

78 s can be detected and sampled effectively by EUS-fine needle aspiration (FNA).

79 mpus America Corp, Melville, NY) followed by EUS-RTFNA with the Pentax FG-32PUA (Pentax-Precision Ins

80 If no stone was found by EUS, ERCP would not be performed and patients were follo

81 seven patients, GOV were only identified by EUS.

82 The mean tumor size measured by EUS was 26.1 mm (range: 20-42 mm).

83 or EPI, diagnosis of chronic pancreatitis by EUS and endoscopic pancreatic function testing and treat

84 patients who were positive for CBD stones by EUS, nine had successful ERCP, one failed ERCP (later tr

85 8 patients without evidence of CBD stones by EUS, no false-negative case was noted during the three-m

86 confirmed in 32 (1.6%) cases, 30 of them by EUS-FNA, and 2 by surgery.

87 50% or more reduction of tumor thickness by EUS postchemotherapy continues to be the best measure fo

88 Of 113 subjects with lung cancer, EUS was performed as a first test (after CT scan) for di

89 tively enrolled in a blinded study comparing EUS, MRI, and examination under anesthesia (EUA).

90 rbidities, and tumor stage determined by CT, EUS, and EUS FNA were associated with treatment decision

91 mpare the performance characteristics of CT, EUS, and EUS FNA for preoperative nodal staging of esoph

92 hester were prospectively evaluated with CT, EUS, and EUS FNA.

93 EUS-guided fine needle aspiration cytology (EUS-FNA), and the newest emerging application is EUS-gui

94 d electrogram amplitude that best determines EUS is unknown.

95 supraspinal connections on chronic detrusor-EUS coordination.

96 show that the extent of recovery of detrusor-EUS coordination depends on injury severity and the degr

97 jured rats, the chronic recovery of detrusor-EUS coordination was very incomplete and correlated to d

98 njury site and complete recovery of detrusor-EUS coordination.

99 Among those with diagnostic EUS-RTFNA (91%), the sensitivity for malignancy (confirm

100 sible on color Doppler or even power Doppler EUS.

101 Hemorrhagic complications during EUS-guided pseudocyst drainage can occur, because the ve

102 FNA samples from each of 250 patients during EUS.

103 urting arterial bleeding precipitated during EUS-guided pseudocyst drainage which stopped instantaneo

104 diagnostic efficacy of linear echoendoscopy (EUS) for CBD stones.

105 d that alcohol is not required for effective EUS-guided pancreatic cyst ablation, and when alcohol is

106 Ultrasound elastography (EUS) is a new method that shows structural changes in ti

107 Low MI contrast enhanced EUS technique is expected to improve the differential di

108 and specificity of low MI contrast enhanced EUS using TIC analysis were 93.75% (95% CI = 77.77-98.91

109 and specificity of low MI contrast enhanced EUS using TIC were sensitivity and specificity of low MI

110 low mechanical index (MI) contrast-enhanced EUS.

111 during procedural sedation for elective ERCP/EUS by reducing the frequency of hypoxemia, severe hypox

112 cent findings regarding the accuracy of EUS, EUS-guided fine needle aspiration (EUS-fine needle aspir

113 The combination of EUS-FNA and EBUS-FNA (EUS plus EBUS) had higher estimated sensitivity (93% [39

114 les devoted to the standard applications for EUS, but most of the emphasis is on EUS-FNA and EUS-guid

115 T) findings of a lung mass were enrolled for EUS and results were compared with those from CT and pos

116 An emerging indication for EUS is the diagnosis and staging of cholangiocarcinoma.

117 , 67% of patients who underwent alcohol-free EUS-guided cyst chemoablation had complete ablation of c

118 Under EUS guidance, a 19-gauge EUS fine needle was advanced transhepatically into the p

119 All patients had EUS performed at the time of consultation and on complet

120 This new method of identifying EUS provides complimentary information to the electrogra

121 mulus train duration produced a reduction in EUS ENG activity before and after SCT.

122 ew highlights advances over the last year in EUS in the evaluation of pancreatic neuroendocrine tumor

123 From its inception, EUS has been primarily utilized for staging cancer, asse

124 en the pursuit of new technologies including EUS.

125 Minimally invasive EUS-FNA with RT-PCR is capable of detecting expression o

126 FNA), and the newest emerging application is EUS-guided interventions.

127 Linear EUS had sensitivity, specificity, positive and negative

128 Linear EUS is safe and efficacious for the diagnosis of occult

129 When a CBD stone was disclosed by linear EUS, ERCP with stone extraction was performed.

130 ll on narrow-band imaging, and with a 20-MHz EUS probe, it was designated eusT1bN0.

131 s significantly greater than the accuracy of EUS morphology (57 of 112, 51%) or cytology (64 of 109,

132 on recent findings regarding the accuracy of EUS, EUS-guided fine needle aspiration (EUS-fine needle

133 The accuracy of EUS-FNA in patients with previously failed biopsy proced

134 negative predictive values, and accuracy of EUS-FNA with histology analysis of the specimens for dia

135 creatitis may be enhanced by ANN analysis of EUS imaging.

136 d and is now dominated by the application of EUS-guided fine needle aspiration cytology (EUS-FNA), an

137 e studies on the therapeutic applications of EUS have been published.

138 ill focus on the therapeutic applications of EUS.

139 The combination of EUS-FNA and EBUS-FNA (EUS plus EBUS) had higher estimate

140 inal diagnosis was based on a combination of EUS-FNA, surgery and follow-up of minimum 6 months in ne

141 EUS-FNA) permits cytological confirmation of EUS findings.

142 A multicenter prospective evaluation of EUS-FNA for primary diagnosis, staging, and/or follow-up

143 onic bursts and phasic firing independent of EUS activity.

144 The performance of EUS-FNA for diagnosis of pancreatic metastases was analy

145 The results of EUS imaging, cyst fluid cytology, and cyst fluid tumor m

146 , there is controversy regarding the role of EUS fine-needle aspiration, the findings of which may en

147 As for the role of EUS in pancreatic cancer, recent technical advances in c

148 The role of EUS in restaging following neoadjuvant therapy remains c

149 last year demonstrate the important role of EUS in the diagnosis, prognosis, and treatment of pancre

150 e needle aspiration samples, and the role of EUS screening for patients with multiple endocrine neopl

151 data and some uncertainty as to the role of EUS within the diagnostic algorithm for patients with su

152 The role of EUS-guided fine-needle aspiration (EUS FNA) in this sett

153 The sensitivity of EUS-FNA for pancreatic adenocarcinoma is excellent (more

154 Cytological study of EUS-guided fine needle aspiration from the mass was sugg

155 e the diagnostic yield and optimal timing of EUS in patients with an intermediate or high likelihood

156 highlights recent advances in the utility of EUS in the clinical management of pancreatic neuroendocr

157 As utilization of EUS is increasing, so is the evolution of the discipline

158 The diagnostic yields of EUS-FNA and CT for detection of metastases to the CLNs w

159 ho have a few nondiagnostic abnormalities on EUS, these results have poor correlation with the result

160 chronic pancreatitis should not be based on EUS findings alone.

161 ll was normal with no evidence of disease on EUS-guided biopsy in eight of 11 patients.

162 s, and fluorescence in-situ hybridization on EUS-FNA samples may increase the yield and prove to be b

163 ions for EUS, but most of the emphasis is on EUS-FNA and EUS-guided interventions.

164 accurate than CT (87% vs. 51%; P < 0.001) or EUS (87% vs. 74%; P = 0.012) for nodal staging.

165 tractions were 252% larger and evoked phasic EUS activation 2.6 times as often as responses below thr

166 Posttreatment EUS findings did not correlate well with surgical pathol

167 sewhere and did not return for posttreatment EUS.

168 ions has particular evolutionary properties (EUS, CS, SPR and MI).

169 the different neural pathways that regulate EUS activity are important to consider when inducing ner

170 tations at presentation, blood test results, EUS and ERCP findings, and clinical manifestations durin

171 f 44 cases with resectable tumor on CT scan, EUS-FNA avoided thoracotomy in 14% of cases.

172 t delineating electrically unexcitable scar (EUS) within low-voltage infarct regions will locate reen

173 RF ablation lines connecting selected EUS regions abolished all inducible VTs in 10 patients (

174 adder and evoke external urethral sphincter (EUS) contraction (guarding reflex) to maintain continenc

175 ontractions and external urethral sphincter (EUS) electromyographic (EMG) activation during urodynami

176 External urethral sphincter (EUS) electromyography (EMG) was typical for the rat, wit

177 er pressure and external urethral sphincter (EUS) electroneurogram (ENG) evoked by PN stimulation bef

178 mic bursting of external urethral sphincter (EUS) EMG and expulsion of urine from the urethral meatus

179 External urethral sphincter (EUS) injections resulted in labelling of pudendal motone

180 The external urethral sphincter (EUS) plays a crucial role in maintaining urinary contine

181 d muscle of the external urethral sphincter (EUS) that is controlled by spinal and supraspinal circui

182 For initial anatomic staging, EUS results have consistently shown more than 80% accura

183 growth in the United States has been steady, EUS is exploding in areas of Asia and Eastern Europe.

184 , while FDG-PET/CT may be more accurate than EUS-FNA and CT scan for predicting nodal status and comp

185 ng that FDG-PET/CT may be more accurate than EUS-FNA and CT scan for predicting nodal status and comp

186 NA has higher sensitivity than TBNA and that EUS plus EBUS may allow near-complete minimally invasive

187 We hypothesized that EUS would detect early GOV and decrease the need for liv

188 nfirmation in other studies but suggest that EUS plus EBUS may be an alternative approach for mediast

189 The EUS responds to cutaneous as well as genital and rectal

190 However, the EUS EMG response is significantly larger when induced by

191 cy (+467%, n = 16) and tonic activity in the EUS (+56%, n = 7) whilst bursting activity in the EUS be

192 +56%, n = 7) whilst bursting activity in the EUS became desynchronised.

193 al nervous system neurons that innervate the EUS and the bladder in the female.

194 the lumbosacral plexus, which innervates the EUS.

195 omatic or visceral sources that modulate the EUS is lacking.

196 activation, anatomical reinnervation of the EUS demonstrated by retrograde neuronal labeling, normal

197 The activity of the EUS is modulated by bladder and urethra sensory neurons.

198 udy were to characterize the response of the EUS to perineal skin, genital, rectal, and urethral mech

199 the degree of coordinated activation of the EUS varied with the severity of initial injury and the d

200 ibition of the bladder and activation of the EUS, but mid-frequency (33 Hz) stimulation produced a mi

201 ion of the bladder without activation of the EUS.

202 bladder (micturition reflex) and relaxes the EUS (augmenting reflex).

203 The indications and role of therapeutic EUS have expanded rapidly in recent years.

204 rther expand the applications of therapeutic EUS.

205 lly, we will introduce potential therapeutic EUS interventions in the treatment of pancreatic neuroen

206 taging distant metastases (M), and therefore EUS is usually performed after a body imaging modality s

207 o provides a glimpse into the future through EUS-guided interventions.

208 ircuit isthmuses identified were adjacent to EUS.

209 ex voiding frequency (-60%, n = 7) and tonic EUS EMG activity (-38%, n = 6) or completely inhibited v

210 ow this threshold urethral flow evoked tonic EUS activity, indicative of the guarding reflex, that wa

211 Staging included endoscopic ultrasonography (EUS) and laparoscopy.

212 laparoscopy and endoscopic ultrasonography (EUS) and to improve R0 resection rates and tolerance by

213 tudies show that endoscopic ultrasonography (EUS) correlates well with endoscopic retrograde cholangi

214 ients undergoing endoscopic ultrasonography (EUS) fine-needle aspiration (FNA).

215 RPOSE OF REVIEW: Endoscopic ultrasonography (EUS) has taken on more of a therapeutic role in recent y

216 Analysis of endoscopic ultrasonography (EUS) images with an artificial neural network (ANN) prog

217 Endoscopic ultrasonography (EUS) may offer a diagnostic tool through the combination

218 Endoscopic ultrasonography (EUS) may replace endoscopic retrograde cholangiopancreat

219 the accuracy of endoscopic ultrasonography (EUS) to diagnose chronic pancreatitis.

220 raphy (ERCP) and endoscopic ultrasonography (EUS) under procedural sedation with a combination of opi

221 laparoscopy and endoscopic ultrasonography (EUS).

222 re therapy using endoscopic ultrasonography (EUS).

223 ach, as shown by endoscopic ultrasonography (EUS).

224 aging (MRI), and endoscopic ultrasonography (EUS).

225 t esophagoduodenoscopy with ultrasonography (EUS) that showed a 3- x 2-cm flat nodular mass with an 8

226 determine accuracy of endoscopic ultrasound (EUS) and magnetic resonance imaging (MRI) for evaluation

227 rd pancreaticobiliary endoscopic ultrasound (EUS) and other imaging modalities in the clinical manage

228 Here we evaluate endoscopic ultrasound (EUS) as on objective method to evaluate pretreatment dis

229 increasingly used in endoscopic ultrasound (EUS) for characterization of microvascularization, diffe

230 Endoscopic ultrasound (EUS) has a vital diagnostic role in pancreatic disorders

231 Endoscopic ultrasound (EUS) has emerged as the diagnostic measure of choice in

232 Endoscopic ultrasound (EUS) has gained increasing attention as a useful imaging

233 he clinical impact of endoscopic ultrasound (EUS) in staging NSCLC in absence of mediastinal lymphade

234 eatography (ERCP) and endoscopic ultrasound (EUS) in the management of patients with pancreatic-bilia

235 Endoscopic ultrasound (EUS) is a sensitive method for detection of GOV.

236 Endoscopic ultrasound (EUS) is a valuable tool in the diagnosis and management

237 Endoscopic ultrasound (EUS) is an important new tool in the staging of pancreat

238 Endoscopic ultrasound (EUS) is one of the fastest growing areas within gastroin

239 Endoscopic ultrasound (EUS) revealed a heteroechoic solid mass originating from

240 rtal venous blood via endoscopic ultrasound (EUS) to count portal venous circulating tumor cells (CTC

241 e include the role of endoscopic ultrasound (EUS), surgery in ZES patients with MEN1, pancreaticoduod

242 xamine the utility of endoscopic ultrasound (EUS), which is increasingly used in this setting to over

243 BACKGROUND & AIMS: Endoscopic ultrasound (EUS)-guided chemoablation with ethanol lavage followed b

244 Under EUS guidance, a 19-gauge EUS fine needle was advanced tr

245 ons (mean size, 3.3 cm) were aspirated under EUS guidance (median passes, three) and the cytologic di

246 ients did not undergo MRI; 1 did not undergo EUS or EUA; and consensus could not be reached for 1.

247 portal venous blood from patients undergoing EUS.

248 CLC and negative control subjects undergoing EUS for benign disease.

249 of previous extrapancreatic cancer underwent EUS-FNA from January/1997 to December/2010.

250 patients from the EBUS-TBNA group underwent EUS-FNA.

251 e hundred forty-one (341) patients underwent EUS and FNA of a pancreatic cystic lesion; 112 of these

252 37 patients underwent EUS-FNA for probable pancreas metastases.

253 mly assigned to 1 of 2 groups that underwent EUS-guided pancreatic cyst lavage with either 80% ethano

254 tion of CBD stones in patients who underwent EUS > 7 days after the initial clinical presentation (od

255 suspected choledocholithiasis who underwent EUS between June 2009 and January 2012 were retrospectiv

256 ients with diverse pathologies who underwent EUS with FNA, despite limited tissue sampling for FISH a

257 rgery, 11 of 16 patients underwent follow-up EUS.

258 When EUS-FNA was compared with EUS size criteria in lymph nod

259 bladder voiding contractions coincident with EUS EMG activation, anatomical reinnervation of the EUS

260 When EUS-FNA was compared with EUS size criteria in lymph node evaluation, specificity

261 locoregional staging is best performed with EUS-FNA, with CT scan of the thorax and abdomen and FDG-

262 Mediastinal lymph nodes were sampled with EUS-FNA in patients with NSCLC and negative control subj

263 mparison of pathologic tumor (pT) stage with EUS-predicted tumor stage showed apparent downstaging in

264 firing during micturition in synchrony with EUS activity but, in addition, showed both tonic bursts